Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR) is a healthcare company (biotechnology) based in the United States. The share price is $35.91, down 1.45% on the day, which values the company at $1.23B. Price as of 18 Nov 2026, 10:38 UTC, from Yahoo Finance.

Key facts

Share price
$35.91−1.45% today
Market value
$1.23B
Funk Score
27/100
Against its own history
Above its usual priceusual price $27.82
200-week average
$29.5122% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Nektar Therapeutics in more detail

NKTR trades at -3.6× next year's expected earnings, 23.5× sales. Measured against its own history, the price is 29% above what its usual multiples would imply ($27.82) — above its usual price. It sits 22% above its 200-week average of $29.51.

Over the last five fiscal years Nektar Therapeutics has compounded revenue -18.4% a year. Its Funk Score is 27 out of 100 (financial strength 3.3, profitability 2.8, growth 0.7, value 4.1, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

Nektar Therapeutics (NKTR): questions and answers

What is NKTR's PEG ratio?

Nektar Therapeutics's PEG ratio is 0.31 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Nektar Therapeutics's market cap?

Nektar Therapeutics is valued at $1.23B at a share price of $35.91.

Is NKTR overvalued or undervalued?

Against its own history, NKTR is above its usual price: the price is 29% above the $27.82 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is NKTR above its 200-week moving average?

Yes. NKTR is 21.7% above its 200-week average of $29.51. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Nektar Therapeutics growing?

Over the last five fiscal years Nektar Therapeutics's revenue grew -18.4% a year; over ten years revenue grew -13.3% a year.

Does NKTR pay a dividend?

Nektar Therapeutics does not currently pay a regular dividend.

Cite this page

Funkfolio, “Nektar Therapeutics (NKTR) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/NKTR

Underlying data: Yahoo Finance; company filings with the SEC.